Abstract 1499 Investigating the functions of Epstein-Barr Virus Gene BNLF2b in lytic induction therapy targeting EBV positive gastric cancers

Introduction: Epstein-Barr Virus (EBV) is a highly contagious, oncogenic virus, infecting over 95% of the adult population worldwide. Upon infection, EBV establishes a latent state within host cells, evading immune detection. However, under conditions such as stress or immune suppression, the virus can reactivate, entering the lytic cycle, during which it rapidly replicates, causing host cell lysis and death. Leveraging this mechanism, lytic induction therapy has emerged as a promising therapeutic approach, specifically targeting EBV-infected tumor cells by inducing their transition from latency to the lytic phase.